EIKN · Eikon Therapeutics, Inc.
$11.95
+1.20 (+11.16%)
At close · Aug 21
Market Cap
$582.27M
Shares
54.17M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.75
Open$11.90
Day$10.40–12.04
Available close range$8.36–16.26
Avg vol 30d381K
Short int4.9M · 9.0% float · 20.0d
Short vol78%
DataFeb 2026–Aug 2026
Filing10-Q · Aug 13
The closing range uses available history since Feb 5, 2026; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+6%
above
RSI (14)
54
neutral
MACD trend
Positive
52-week position
30%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+12%
trailing
6-month return
−22%
trailing
Relative strength
−33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+46% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.00% of float · ▲ +5.4% MoM · 20.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
76 holders — 13F breadth
Squeeze score
81
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
9.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+6%
Bullish
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
30%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+46% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.00% of float · ▲ +5.4% MoM · 20.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
76 holders — 13F breadth
Price context
position in its available closing range
Range low $8
Now $11 · 30%
Range high $16
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EIKN
this stock
Eikon Therapeutics, Inc.
|
$582.27M | — | — | — | 9.0% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EIKN | +4.1% | +11.8% | -22.0% | +16.7% | — |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +6.0% | +8.4% | -33.2% | +14.6% | — |
Key facts
CIK
1861123
CUSIP
282564103
13F (30d)
75 filings
73 filers
Visit website
Investor relations